// App-Quantinova.ai

: Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials

Researchers

Presenter

  • Michael D. Tarantino

Principal Investigators

  • Jenny M. Despotovic

  • John Roy

  • John Grainger

  • Nichola Cooper

  • Donald Beam

  • Ashok Raj

  • Alexey A. Maschan

  • June Kim

  • Melissa Jeanne Eisen

Medical Centers

  • Bleeding & Clotting Disorders Institute, Peoria, IL

  • Professor of Pediatrics and Medicine, University of Illinois College of Medicine-Peoria, Peoria, IL

  • Texas Children's Cancer and Hematology Centers, Houston, TX.

  • Children's Health Queensland & Pathology Queensland, South Brisbane QLD, Australia

  • University of Queensland, St. Lucia, Australia

  • Department of Pathology, Royal Manchester Children's Hospital, Manchester, United Kingdom

  • Faculty of Medical & Human Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • Imperial College, London, United Kingdom

  • Cook Childrens Medical Center, Fort Worth, TX.

  • Pediatric Cancer and Blood Disorders Clinic,Louisville KY,United States

  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

  • Amgen Inc, Thousand Oaks, CA

Locations

  • United States

  • Australia

  • United Kingdom

  • Russia

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • Romiplostim

Outcome

  • N/A

Study Design

  • Placebo Control

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved